Table 2.

Relationship between prebiopsy clinical indicators and Gleason score and evaluating the diagnostic performance of each variable for predicting PCa and csPCa using receiver operating characteristic curve analysis.

Indicators	Relationship between clinical indicators and Gleason Score		ROC curve analysis for diagnosis of PCa			ROC curve analysis for diagnosis of csPCa
	R	p-value	AUC	95% CI	p-value	AUC	95% CI	p-value
Age	0.245	<0.001	0.616	0.559–0.673	<0.001	0.645	0.586–0.704	<0.001
f-PSA	0.067	0.199	0.502	0.441–0.563	0.952	0.534	0.469–0.600	0.276
t-PSA	0.282	< 0.001	0.628	0.569–0.688	<0.001	0.668	0.606–0.730	<0.001
f/t-PSA	−0.323	< 0.001	0.310	0.257–0.365	<0.001	0.296	0.242–0.351	<0.001
PV	−0.275	<0.001	0.325	0.270–0.380	<0.001	0.337	0.280–0.394	<0.001
PSAD	0.442	< 0.001	0.734	0.682–0.787	<0.001	0.765	0.711–0.819	<0.001
PI-RADS score	0.654	< 0.001	0.863	0.825–0.900	<0.001	0.864	0.827–0.901	<0.001
T2WI score	0.632	<0.001	0.848	0.809–0.887	<0.001	0.851	0.812–0.889	<0.001
DWI score	0.667	< 0.001	0.856	0.818–0.894	<0.001	0.859	0.821–0.897	<0.001
Total score	0.664	< 0.001	0.900	0.869–0.931	<0.001	0.903	0.872–0.933	<0.001

fPSA, free PSA; tPSA, total PSA; f/tPSA, free/total PSA; PV, prostate volume; PSAD, PSA density; PI-RADS score, prostate imaging reporting and date system score; T2WI score, T2WI score referring to PI-RADS v2; DWI score, DWI score referring to PI-RADS score; csPCa, clinical significance prostate cancer; Total score, T2WI score + DWI score.